A pilot study to evaluate the cost-effectiveness of ondansetron and granisetron in fractionated total body irradiation

Clinical Oncology

Volumn 8, Issue 3, 1996, Pages 182-184

  Gibbs, S J ^a,b   Cassoni, A M ^a  

^a MIDDLESEX HOSPITAL   (United Kingdom)

^b ROYAL LONDON HOSPITAL   (United Kingdom)

Author keywords

Bone marrow transplantation; Emesis; Granisetron; Ondansetron; Total body irradiation

Indexed keywords

CYCLOPHOSPHAMIDE; DEXAMETHASONE; ETOPOSIDE; GRANISETRON; ONDANSETRON;

ANTIEMETIC ACTIVITY; ARTICLE; BONE MARROW TRANSPLANTATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; FOLLOW UP; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEUKEMIA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RADIATION DOSE FRACTIONATION; RANDOMIZED CONTROLLED TRIAL; VOMITING; WHOLE BODY RADIATION;

EID: 0029901648     PISSN: 09366555     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0936-6555(96)80043-4     Document Type: Article

References (3)

1. Dilly S. Granisetron: Clinical safety and tolerance. Semin Oncol 1994;21(3 Suppl 5):10-14.
2. 3 receptor antagonists. Drug Des Deliv 1988;3:273-95.
3. 3 receptor antagonist, for the prevention of radiation induced emesis during total body irradiation. Bone Marrow Transplant 1991;7:439-41.